Semperit (SEM) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
26 Nov, 2025Executive summary
Q1 2025 revenue declined 13.8% year-over-year to EUR 151.7 million, with EBITDA down 51.6% to EUR 11.1 million and margin at 7.3%, reflecting weak demand, project delays, and US tariff conflicts.
Earnings after tax turned negative at EUR -7.2 million, with EPS at EUR -0.35.
Free cash flow increased to EUR 8.7 million due to lower CapEx.
Order intake and order book improved in March and April, exceeding prior year levels, especially in industrial applications.
Financial position remains solid with EUR 128.4 million in cash and a 46% equity ratio.
Financial highlights
Revenue declined 13.8% year-over-year to EUR 151.7 million; EBITDA fell 51.6% to EUR 11.1 million.
EBIT dropped to EUR -1.3 million from EUR 11.6 million year-over-year; EBIT margin at -0.9%.
Free cash flow rose to EUR 8.7 million, mainly from reduced CapEx.
Net debt/EBITDA increased to 1.4x; net financial debt at EUR 100.2 million.
Dividend of EUR 0.50 per share paid out in April 2025.
Outlook and guidance
Operational EBITDA guidance for 2025 confirmed at EUR 65–85 million, with EUR 5 million in digitalization project costs expected.
Recovery expected in H2 2025, but outlook remains uncertain due to ongoing trade negotiations and US tariff policy.
OpEx and CapEx guidance maintained, with flexibility to adapt investments to market conditions.
Latest events from Semperit
- Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 202424 Dec 2025 - Q3 2025 profit turnaround and strong order intake support a confident full-year EBITDA outlook.SEM
Q3 202517 Dec 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025